RecruitingNCT06203249
Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
Microecology and Host Immunity in Patients With Anti-melanoma Differentiation Associated Gene 5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
Sponsor
Chinese PLA General Hospital
Enrollment
50 participants
Start Date
Jan 20, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study was to analyze the relationship between the microbial community, host immunity and the presence or absence of concurrent rapidly progressive interstitial lung disease patients with anti-MDA5 antibody positive dermatomyositis.
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Inclusion Criteria5
- Patients who meet the diagnostic criteria of dermatomyositis and anti-MDA 5 antibody positive.
- Anti-MDA5 antibody positive DM patients with RPILD meet the diagnostic criteria for RPILD.
- Must have undergone bronchoalveolar lavage.
- Age≥18 years old.
- Patients who signed informed consent forms
Exclusion Criteria5
- Patients who had other connective tissue diseases.
- Patients with ILD or RPILD caused by infection, tumors, drugs, biochemistry and other factors.
- Pregnant or lactating patients.
- The patient also participated in any other clinical trial.
- Disagreement for inclusion in this study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06203249